

# David R Ferry

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11184105/publications.pdf>

Version: 2024-02-01

26  
papers

5,015  
citations

279778

23  
h-index

552766

26  
g-index

26  
all docs

26  
docs citations

26  
times ranked

5326  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2014, 383, 31-39.	13.7	1,833
2	Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. <i>Lancet, The</i> , 2007, 370, 143-152.	13.7	520
3	Hepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin. <i>Journal of Clinical Oncology</i> , 2002, 20, 1668-1676.	1.6	377
4	Calcium channels: direct identification with radioligand binding studies. <i>Trends in Pharmacological Sciences</i> , 1982, 3, 431-437.	8.7	295
5	Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. <i>Lancet Oncology, The</i> , 2014, 15, 894-904.	10.7	270
6	Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. <i>International Journal of Oncology</i> , 2009, 34, 1629-36.	3.3	251
7	[42] Assay for calcium channels. <i>Methods in Enzymology</i> , 1985, 109, 513-550.	1.0	181
8	Evidence for multiple receptor sites within the putative calcium channel. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1982, 321, 80-83.	3.0	125
9	A Phase II Study of Gefitinib Monotherapy in Advanced Esophageal Adenocarcinoma: Evidence of Gene Expression, Cellular, and Clinical Response. <i>Clinical Cancer Research</i> , 2007, 13, 5869-5875.	7.0	120
10	Identification of putative calcium channels in skeletal muscle microsomes. <i>FEBS Letters</i> , 1982, 148, 331-337.	2.8	101
11	Gefitinib and <i>EGFR</i> Gene Copy Number Aberrations in Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2279-2287.	1.6	100
12	Solubilization and partial purification of putative calcium channels labelled with [3H]-nimodipine. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1983, 323, 279-291.	3.0	99
13	Purification of the putative calcium channel from skeletal muscle with the aid of [3H]-nimodipine binding. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1983, 323, 1-11.	3.0	97
14	Photoaffinity labelling of Ca <sup>2+</sup> channels with [3 H]azidopine. <i>FEBS Letters</i> , 1984, 169, 112-118.	2.8	91
15	Stereoselective photoaffinity labelling of the purified 1,4-dihydropyridine receptor of the voltage-dependent calcium channel. <i>FEBS Journal</i> , 1986, 161, 603-609.	0.2	86
16	(?)-3H-desmethoxyverapamil labelling of putative calcium channels in brain: autoradiographic distribution and allosteric coupling to 1,4-dihydropyridine and diltiazem binding sites. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1984, 327, 183-187.	3.0	82
17	Novel 1,4-Dihydropyridine (Bay K 8644) Facilitates Calcium-Dependent [3H]Noradrenaline Release from PC 12 Cells. <i>Journal of Neurochemistry</i> , 1984, 42, 1186-1189.	3.9	63
18	Resolving the structure of the Ca <sup>2+</sup> channel by photoaffinity labelling. <i>Trends in Pharmacological Sciences</i> , 1987, 8, 95-100.	8.7	61

#	ARTICLE	IF	CITATIONS
19	Target size analysis and molecular properties of Ca <sup>2+</sup> channels labelled with [3H]verapamil. FEBS Journal, 1984, 141, 177-186.	0.2	54
20	Differential labelling of putative skeletal muscle calcium channels by [3H]-nifedipine, [3H]-nitrendipine, [3H]-nimodipine and [3H]-PN 200 110. Naunyn-Schmiedeberg's Archives of Pharmacology, 1983, 323, 276-277.	3.0	53
21	Identification of Voltage Operated Calcium Channels by Binding Studies: Differentiation of Subclasses of Calcium Antagonist Drugs with <sup>3</sup> H-Nimodipine Radioligand Binding. Journal of Receptors and Signal Transduction, 1983, 3, 177-190.	1.2	51
22	The Genetic Basis of Resistance to Cancer Chemotherapy. Annals of Medicine, 1995, 27, 157-167.	3.8	31
23	125I-iodipine*, a new high affinity ligand for the putative calcium channel. Naunyn-Schmiedeberg's Archives of Pharmacology, 1984, 325, 186-189.	3.0	25
24	Exposureâ€“response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2018, 82, 77-86.	2.3	18
25	REGARD: A phase III, randomized, double-blinded trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GE) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing combination therapy.. Journal of Clinical Oncology, 2013, 31, 1BA5-1BA5.	1.6	16
26	Effects of prior bevacizumab (B) use on outcomes from the VELOUR study: A phase III study of aflibercept (Afl) and FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen.. Journal of Clinical Oncology, 2012, 30, 3505-3505.	1.6	15